en · de · es · fr · pt
tesamorelin-notes.peptides1004.com › News › Identity And Development Background — What the Evidence Shows

Identity And Development Background — What the Evidence Shows

By Editorial Desk · published 2025-10-28 · last reviewed 2025-11-24 · News

The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2025-11-24. Anything still debated is marked as such rather than presented as settled.

Identity and Development Background

Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.

Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.

Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.

Background and Clinical Profile

Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.

Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.

Tesamorelin at a glance

PropertyValueNotes
Molecular classSynthetic 44-residue GHRH analogSequence matches human GHRH(1-44); differs only at the N-terminus
Nominal molecular massApproximately 5,136 Da (free base)Small variation arises from counterion and salt form
AppearanceWhite to off-white lyophilized powderSupplied in single-use vials intended for reconstitution
Solubility classFreely soluble in waterPractically insoluble in nonpolar organic solvents
Typical storage2 to 8 degrees Celsius, protected from lightReconstituted material is handled according to label instructions

Molecular Background and Receptor Mechanism

Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.

Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.

Related pages on this site

tesamorelin 背景与作用机制

tesamorelin 是一种人工合成的四十四肽,序列与内源性生长激素释放激素(GHRH)的 1-44 片段一致,区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割,从而延长分子在循环中的存留时间。作为肽类分子,它难以经胃肠道吸收,文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物,以区别于生长激素本身。

作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶,升高细胞内 cAMP,再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点,生长激素仍以脉冲方式分泌,而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生,构成完整的生长激素轴响应。

Further detail

This PFS benefit was consistent across subgroups with individual high-risk cytogenetic abnormalities, including patients with del(17p). PFS was also longer with IRd versus placebo- in patients with 1q21 amplification, and in the "expanded high-risk" group, defined as those with high-risk cytogenetic abnormalities and/or 1q21 amplification. IRd demonstrated substantial benefit compared with placebo in relapsed/refractory multiple myeloma patients with high-risk and standard-risk cytogenetics, and improves the poor PFS associated with high-risk cytogenetic abnormalities.

The main method of treatment for potential death from signaling-related diseases involves either increasing or decreasing the susceptibility of apoptosis in diseased cells, depending on whether the disease is caused by either the inhibition of or excess apoptosis. For instance, treatments aim to restore apoptosis to treat diseases with deficient cell death and to increase the apoptotic threshold to treat diseases involved with excessive cell death. To stimulate apoptosis, one can increase the number of death receptor ligands (such as TNF or TRAIL), antagonize the anti-apoptotic Bcl-2 pathway, or introduce Smac mimetics to inhibit the inhibitor (IAPs). The addition of agents such as Herceptin, Iressa, or Gleevec works to stop cells from cycling and causes apoptosis activation by blocking growth and survival signaling further upstream. Finally, adding p53-MDM2 complexes displaces p53 and activates the p53 pathway, leading to cell cycle arrest and apoptosis. Many different methods can be used either to stimulate or to inhibit apoptosis in various places along the death signaling pathway. Apoptosis is a multi-step, multi-pathway cell-death programme that is inherent in every cell of the body. In cancer, the apoptosis cell-division ratio is altered. Cancer treatment by chemotherapy and irradiation kills target cells primarily by inducing apoptosis.

The Medic class is equipped with a super nail gun, concussion grenades and a medical kit that can be used either to heal teammates or expose opponents to a contagious infection that drains health. The Heavy Weapons class is armed with a powerful minigun, and can sustain more damage than any other class. However, the Heavy is significantly slower than the other classes. The Pyro class is equipped with a flamethrower and an incendiary rocket launcher, both of which can set enemies on fire. Pyros also carry several napalm grenades for the same purpose. The Spy class differs significantly in style from other classes, as he can disguise himself to look like any other class on either side. The Spy is equipped with a knife to kill enemy players in one hit by stabbing them in the back, a tranquilizer gun to slow down opponents and a hallucination grenade which spouts gas to confuse them. Spies also possess the ability to feign death, allowing them to use their backstab ability more effectively. The Engineer class builds structures to support their team, such as sentry guns to defend key points, ammunition dispensers and teleporters. Engineers have the ability to replenish a teammate's armor by tapping them with their wrench. In addition, the Engineer is armed with EMP grenades that detonates any explosive ammunition within its range, as well as a shotgun for backup.

== Properties == According to the Biopharmaceutical Classification System (BCS), gliclazide falls under the BCS Class II drug, which is poorly soluble and highly permeable. Water solubility = 0.027mg/L

Substitution reactions that proceed through a free carbocation intermediate, such as unimolecular substitution reactions, lead to non-stereospecific addition of substituents which results in racemization. Although unimolecular elimination reactions also proceed through a carbocation, they do not result in a chiral center. They result instead in a set of geometric isomers in which trans/cis (E/Z) forms are produced, rather than racemates. In a unimolecular aliphatic electrophilic substitution reaction, if the carbanion is planar or if it cannot maintain a pyramidal structure, then racemization should occur, though not always. In a radical-substitution reaction, if the formation of the free radical takes place at a chiral carbon, then racemization is almost always observed. The rate of racemization (from L-forms to a mixture of L-forms and D-forms) is used as a way of dating biological samples in tissues with slow rates of turnover, forensic samples, and fossils in geological deposits. This technique is known as amino acid dating.

Sources: en.wikipedia.org

Supporting material

The British critical psychiatrist Joanna Moncrieff has critiqued the use and study of ketamine and related drugs like psychedelics for treatment of psychiatric disorders, highlighting concerns including excessive hype around these drugs, questionable biologically-based theories of benefit, blurred lines between medical and recreational use, flawed clinical trial findings, financial conflicts of interest, strong expectancy effects and large placebo responses, small and short-term benefits over placebo, and their potential for difficult experiences and adverse effects, among others.

A number of factors are known to affect GH secretion, such as age, sex, diet, exercise, stress, and other hormones. Young adolescents secrete GH at the rate of about 700 μg/day, while healthy adults secrete GH at the rate of about 400 μg/day. Sleep deprivation generally suppresses GH release, particularly after early adulthood. Stimulators of growth hormone (GH) secretion include:

== Domestic impact == Psychiatrist Thomas Szasz wrote in 1997, "Over the past thirty years, we have replaced the medical-political persecution of illegal sex users ('perverts' and 'psychopaths') with the even more ferocious medical-political persecution of illegal drug users." Assessing from a health perspective, a study in the Annals of Medicine noted: "The U.S. war on drugs has subjected millions to criminalization, incarceration, and lifelong criminal records, disrupting or altogether eliminating their access to adequate resources and supports to live healthy lives."

This may conflict with other product ions, such as the association product from the reaction with carbon dioxide, H3O+CO2, and the single hydrate of the protonated acetaldehyde ion, C2H5O+(H2O), which also appear at m/z 63, and so it may be unidentifiable in certain samples. However dimethyl sulfide reacts with NO+ by charge transfer, to produce the ion C2H6S+, which appears at m/z 62 in resulting spectra, whereas carbon dioxide does not react with NO+, and acetaldehyde donates a hydride ion, giving a single product ion at m/z 43, C2H3O+, and so dimethyl sulfide can be easily distinguished. Over recent years, advances in SIFT-MS technology have vastly increased the sensitivity of these devices such that the limits of detection now extend down to the single-digit-ppt level.

Sources: en.wikipedia.org

Frequently asked questions

What is tesamorelin made of?

It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.

Is tesamorelin a form of growth hormone?

No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.

Why does the molecule include a hexenoyl group?

Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.

What is tesamorelin?

It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.

Network